As reported july 15, 2016, a patient of unknown age and gender presented for an ire (irreversible electroporation) procedure of the liver.During the procedure, the nanoknife system displayed a communication error however, continued to deliver pulses.The unit was immediately turned off by the treating physician.The unit was rebooted and the treating physician determined to resume the procedure.During the remaining procedure, the patient experienced ventricular tachycardia/ventricular fibrillation for about one minute.Defibrillation was successfully performed on the patient and again, the physician resumed the procedure.It was reported the patient remained stable for the remainder of the procedure.It was reported the nanoknife system is available for return to the manufacturer for evaluation.
|
This medwatch is not to report a device malfunction, but to report an adverse patient effect.There was no report of a device malfunction during the procedure.The unit was not returned for assessment.The customer's reported complaint description of a patient experiencing ventricular fibrillation during nanoknife ablations was confirmed based on information provided by the treating physician.The treating physician used the defibrillator to regulate the heartbeat.Once the patient returned to normal sinus rhythm, the case was completed without further complications.The patient suffered no lasting, permanent harm.Although the complaint is confirmed, a root cause cannot be determined without receiving the unit to evaluate.It was noted that the mass being treated was extremely close to the heart, increasing the risk for arrhythmia.Ventricular fibrillation is a known adverse complication of this procedure.A review of the device history records was performed for the reported serial number (b)(4) for any deviations related to the reported defect of the complaint.The review confirmed that the unit met all material, assembly, and performance specification prior to distribution to this customer account.The nanoknife generator user manual contains the following warning "patients with q-t intervals greater than 550 ms (milliseconds) are at an increased risk for inappropriate energy delivery and arrhythmia.Verification of proper function of a synchronization device before initiating energy delivery is essential in these patients.Asynchronous energy delivery (240 ppm (pulses per minute) or 90 ppm modes) might trigger atrial or ventricular fibrillation, especially in patients with structural heart disease.Ensure that proper interventions (e.G.Defibrillator) and appropriately trained personnel are readily available for dealing with potential cardiac arrhythmias (see section 5.1.3).Using qrs synchronization devices whose output is not compatible with the specifications listed in this manual may result in arrhythmias including ventricular fibrillation.Adequate precautions should be taken for patients with implantable electrical devices.There are potential risks associated with the location of the ablation: near the pericardium (tachycardia), or near the vagus nerve (bradycardia)".In addition, the instructions for use, which is supplied to the user with single electrode probes, lists arrhythmias as a potential adverse effect.The accusync user manual which is supplied to the user with the accusync, states that "the accusync 72 is a 3 or 5 lead ecg (electrocardiograph) monitor which detects the r-wave of the ecg signal and generates a signal for output to an external device for precision ecg synchronization (also called r-wave triggering or gating).It consists of an isolation amplifier that obtains the signal from the patient and processes it for display or recording".A review of the angiodynamics complaint system noted no adverse trends for this complaint type and product family.This type of complaint will continue to be monitored for trends.Complaint # (b)(4).
|